Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands
October agreement advances the U.S. customer program to approximately $5.1 million in committed base services JERUSALEM, Nov. 5, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a contract development and...
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


